Drug Profile

HM 101460

Alternative Names: HM-101460

Latest Information Update: 27 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hanmi Pharmaceutical
Class Antihyperglycaemics; Obesity therapies; Small molecules
Mechanism of Action Glucagon-like peptide-1 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Obesity; Type 2 diabetes mellitus

Most Recent Events

15 Sep 2025 Preclinical trials in Obesity in South Korea (PO)
15 Sep 2025 Preclinical trials in Type 2 diabetes mellitus in South Korea (PO)
15 Sep 2025 Adverse events, pharmacodynamics and pharmacokinetics data from preclinical trials in Type 2 diabetes mellitus and obesity was presented at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD-2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com